Prevalence of Acetylsalicylic Acid Use for Primary Prevention of Cardiovascular Disease Amongst Older Adults From 2017-2021: a Retrospective Cross-Sectional Study.
aged
aspirin
cardiovascular disease
primary prevention
Journal
Canadian geriatrics journal : CGJ
ISSN: 1925-8348
Titre abrégé: Can Geriatr J
Pays: Canada
ID NLM: 101579189
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
Three landmark trials on the use of acetylsalicylic acid (ASA) for primary prevention of cardiovascular disease (CVD) were published in 2018. Since then, major clinical practice guidelines have been updated with recommendations against the routine use of ASA for primary CVD prevention, particularly in older adults. However, little is known about the uptake of this evidence into real world practice. The purpose of this study was to assess the change in ASA usage for primary prevention of CVD in older adults between 2017 and 2021. A retrospective cross-sectional study of ASA use for primary prevention in ambulatory older adults without known CVD in an urban Canadian city was conducted. Seven hundred and fifty-six participants were included. The mean age was 78.9 years (standard deviation 7.9) and 64.8% were female. One hundred and thirty (17.2%) participants used ASA for primary prevention, including 20.3% in 2017, 17.0% in 2018, 21.8% in 2019, 16.3% in 2020, and 11.0% in 2021 ( Use of ASA for primary CVD prevention in older Canadians decreased between 2017 and 2021, suggesting an uptake of clinical trial data and practice guideline recommendations. Focusing on deprescribing of ASA for primary CVD prevention continues to be warranted, given the risks associated with ASA in this population.
Sections du résumé
Background
UNASSIGNED
Three landmark trials on the use of acetylsalicylic acid (ASA) for primary prevention of cardiovascular disease (CVD) were published in 2018. Since then, major clinical practice guidelines have been updated with recommendations against the routine use of ASA for primary CVD prevention, particularly in older adults. However, little is known about the uptake of this evidence into real world practice. The purpose of this study was to assess the change in ASA usage for primary prevention of CVD in older adults between 2017 and 2021.
Methods
UNASSIGNED
A retrospective cross-sectional study of ASA use for primary prevention in ambulatory older adults without known CVD in an urban Canadian city was conducted.
Results
UNASSIGNED
Seven hundred and fifty-six participants were included. The mean age was 78.9 years (standard deviation 7.9) and 64.8% were female. One hundred and thirty (17.2%) participants used ASA for primary prevention, including 20.3% in 2017, 17.0% in 2018, 21.8% in 2019, 16.3% in 2020, and 11.0% in 2021 (
Conclusions
UNASSIGNED
Use of ASA for primary CVD prevention in older Canadians decreased between 2017 and 2021, suggesting an uptake of clinical trial data and practice guideline recommendations. Focusing on deprescribing of ASA for primary CVD prevention continues to be warranted, given the risks associated with ASA in this population.
Identifiants
pubmed: 38045883
doi: 10.5770/cgj.26.693
pii: cgj-26-517
pmc: PMC10684304
doi:
Types de publication
Journal Article
Langues
eng
Pagination
517-523Informations de copyright
© 2023 Author(s).
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood the Canadian Geriatrics Journal’s policy on disclosing conflicts of interest and declare that we have none.
Références
Diabetes Care. 2022 Jan 1;45(Suppl 1):S144-S174
pubmed: 34964815
N Engl J Med. 2018 Oct 18;379(16):1509-1518
pubmed: 30221597
JAMA. 2022 Apr 26;327(16):1577-1584
pubmed: 35471505
Am J Prev Cardiol. 2021 Sep 22;8:100256
pubmed: 34632437
N Engl J Med. 2018 Oct 18;379(16):1519-1528
pubmed: 30221595
N Engl J Med. 2018 Oct 18;379(16):1529-1539
pubmed: 30146931
Can Geriatr J. 2020 Sep 01;23(3):210-215
pubmed: 32904824
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
J Cardiol. 2013 Sep;62(3):165-70
pubmed: 23778008
CMAJ. 2020 Mar 23;192(12):E302-E311
pubmed: 32392513
Ann Intern Med. 2019 Oct 15;171(8):596-598
pubmed: 31330542
Circulation. 2015 Aug 25;132(8):691-718
pubmed: 26246173
J Clin Med. 2022 Feb 22;11(5):
pubmed: 35268267
Lancet. 2019 May 25;393(10186):2155-2167
pubmed: 31226053
CMAJ Open. 2020 Jan 28;8(1):E41-E47
pubmed: 31992558
Circulation. 2002 Jul 16;106(3):388-91
pubmed: 12119259
Risk Manag Healthc Policy. 2010;3:49-60
pubmed: 22312218
Ann Intern Med. 2009 Mar 17;150(6):405-10
pubmed: 19293073
Eur Heart J. 2007 Oct;28(19):2375-414
pubmed: 17726041
Can J Diabetes. 2018 Apr;42 Suppl 1:S162-S169
pubmed: 29650091
Can J Cardiol. 2015 May;31(5):549-68
pubmed: 25936483
JAMA Netw Open. 2021 Jun 1;4(6):e2112210
pubmed: 34152419
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
Lancet. 2018 Sep 22;392(10152):1036-1046
pubmed: 30158069
JAMA. 2019 Jan 22;321(3):277-287
pubmed: 30667501
Can J Cardiol. 2020 May;36(5):596-624
pubmed: 32389335